The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT07221253?viewType=Card&id=D702NC00001&rank=1Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central ConnecticutContacts: Holly Maheu: holly.maheu@hhchealth.org Siobhan Reilly: Siobhan.reilly@hhchealth.org
Referral Line: 860.972.4700
Loading...